RecruitingPhase 2NCT06661915
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Studying Myeloproliferative neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Anand A PatelCity of Hope Comprehensive Cancer Center LAO
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 62 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (25)
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Coral Springs, Coral Springs, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Doral, Doral, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Hollywood, Hollywood, Florida, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States
- University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
- UChicago Medicine Northwest Indiana, Crown Point, Indiana, United States
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06661915 on ClinicalTrials.govOther trials for Myeloproliferative neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07441694Study of INCA036978 in Participants With Myeloproliferative NeoplasmsIncyte Corporation
- RECRUITINGPHASE2NCT07148947Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsUniversity of Washington
- RECRUITINGPHASE2NCT07228624Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesFred Hutchinson Cancer Center
- RECRUITINGNANCT07119970Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)University Hospital, Bordeaux
- RECRUITINGPHASE3NCT06468033P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskPharmaEssentia
- RECRUITINGNANCT05745285Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareUniversity of Miami
- RECRUITINGNCT06480591Evaluation of the Pathobiology of CALR-mutated MPN CellsWake Forest University Health Sciences
- RECRUITINGPHASE3NCT06740916Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients with Aspirin ResistanceSiriraj Hospital